Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MediWound Ltd.MDWD · Entity 296 | Director | September 01, 2026 | September 02, 2026 |
| STRATA Skin Sciences, Inc.SSKN · Entity 72980 | Director | November 17, 2025 | November 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MediWound Ltd.
Report date September 01, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy spouse | 0 |
Reported balance
After 2026-09-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-09-01 · Sale · Disposed 525 · Balance 0 |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy spouse | 525 |
Reported balance
After 2026-09-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-09-01 · Purchase · Acquired 525 · Balance 525 |
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,993 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,993 F2: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Ordinary sharesSEC Table I · non-derivative | Direct | 750 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 750 F1: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date. F2: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $9.64 · Expires 2033-08-15 | Direct | 7,200 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 7,200 F2: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $12.73 · Expires 2034-02-26 | Direct | 7,542 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 7,542 F2: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $18.54 · Expires 2035-02-11 | Direct | 5,600 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 5,600 F2: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $17.60 · Expires 2036-03-04 | Direct | 6,250 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 6,250 F2: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F3: The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
F2: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
F3: The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
STRATA Skin Sciences, Inc.
Report date November 17, 2025 · Filed November 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,766 |
Ending reported balance
After 2025-11-18 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2025-11-17 · Sale · Disposed 5,500 · Balance 12,360 Row 2 · 2025-11-17 · Sale · Disposed 7,200 · Balance 5,160 Row 3 · 2025-11-17 · Sale · Disposed 1,394 · Balance 3,766 Row 4 · 2025-11-18 · Purchase · Acquired 2,168 · Balance 5,934 Row 5 · 2025-11-18 · Purchase · Acquired 2,832 · Balance 8,766 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 2, 2026 20:02 UTC | MediWound Ltd. MDWD · Entity 296 | PurchaseOrdinary Shares | 525 | $12.62 | $6,625.50 |
DisclosureSEC source: 0001178913-26-004392 · ownership.xml · nonDerivative · entry 4 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 525 Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 20:02 UTC | MediWound Ltd. MDWD · Entity 296 | SaleOrdinary Shares | 525 | $12.72 | $6,678.00 |
DisclosureSEC source: 0001178913-26-004392 · ownership.xml · nonDerivative · entry 3 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 0 Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 11:00 UTC | MediWound Ltd. MDWD · Entity 296 | PurchaseOrdinary Shares | 150 | $14.33 | $2,149.50 |
DisclosureSEC source: 0001178913-26-003002 · ownership.xml · nonDerivative · entry 1 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,993 Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 16:35 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseCommon Stock | 2,832 | $1.41 | $3,993.12 |
DisclosureSEC source: 0001051514-25-000016 · form4.xml · nonDerivative · entry 5 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,766 Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 16:35 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseCommon Stock | 2,168 | $1.40 | $3,035.20 |
DisclosureSEC source: 0001051514-25-000016 · form4.xml · nonDerivative · entry 4 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,934 Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 16:35 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | SaleCommon Stock | 1,394 | $1.36 | $1,895.84 |
DisclosureSEC source: 0001051514-25-000016 · form4.xml · nonDerivative · entry 3 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,766 Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 16:35 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | SaleCommon Stock | 7,200 | $1.34 | $9,648.00 |
DisclosureSEC source: 0001051514-25-000016 · form4.xml · nonDerivative · entry 2 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,160 Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 16:35 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | SaleCommon Stock | 5,500 | $1.32 | $7,260.00 |
DisclosureSEC source: 0001051514-25-000016 · form4.xml · nonDerivative · entry 1 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,360 Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 08:31 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | SaleCommon Stock | 1,000 | $0.32 | $320.00 |
DisclosureSEC source: 0001051514-23-000064 · form4.xml · nonDerivative · entry 1 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,602 Read SEC document |
| October 26, 2023 Filed Oct 27, 2023 13:26 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Stock Options · Derivative | 20,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001051514-23-000055 · form4.xml · derivative · entry 1 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-10-26 Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 16:06 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 33,981 | $1.03 | $35,000.43 |
DisclosureSEC source: 0001051514-23-000028 · form4.xml · nonDerivative · entry 1 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,602 F1 · security: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 5, 2023, utilizing the closing price on July 3, 2023. The Restricted Stock will vest at 100%, in equal quarterly installments, over a 12 month period. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 16:06 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 37,838 | $0.93 | $35,000.15 |
DisclosureSEC source: 0001051514-22-000075 · form4.xml · nonDerivative · entry 1 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,621 F1 · security: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 1, 2022. The Restricted Stock Units will vest at 100%, in equal quarterly installments, over a 12 month period. Read SEC document |
| June 15, 2022 Filed Jun 15, 2022 16:07 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 1,050 | $1.04 | $1,092.00 |
DisclosureSEC source: 0001051514-22-000065 · form4.xml · nonDerivative · entry 1 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,783 Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 17:37 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 25,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001051514-21-000038 · form4.xml · nonDerivative · entry 2 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,733 F1 · security: Represents Restricted Stock Units issued to the recipient, in lieu of a portion of the recipient's Board Compensation, on July 20, 2021. The Restricted Stock Units generally vest at 100% on the first anniversary of the date of grant. RSUs have a minimum one year vesting unless as permitted under Section 7.3(c). Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 17:37 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 28,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001051514-21-000038 · form4.xml · nonDerivative · entry 1 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,553 Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 16:35 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 14,228 | $0.00 | $0.00 |
DisclosureSEC source: 0001051514-19-000129 · form4.xml · nonDerivative · entry 1 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,098 F1 · security: Represents Restricted Stock Units issued to the recipient, in lieu of a portion of his Board compensation, on November 22, 2019 at the closing price of $2.46. The Restricted Stock Units will vest 100%, in equal quarterly installments, over a 12 month period. F2 · balance_after: Includes 26,570 fully vested Restricted Stock Units granted on June 8, 2018 and previously reported on Table II. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 10:41 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSTRATA Restricted Stock Units · Derivative | 26,570 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001140361-18-028170 · doc1.xml · derivative · entry 1 Rubinstein Samuel · CIK 0001742152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,570 Underlying: Common Stock · 26,570 shares Expires 2028-06-08 F1 · derivative.exercise_date: Restricted Stock Units will vest 100%, in equal quarterly installments, over a 12 month period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.